United States Patent US 8,771,648: Scope, Claim Architecture, and Patent Landscape for Effervescent Solid Compositions
What does US 8,771,648 claim, in plain scope terms?
US 8,771,648 is directed to solid pharmaceutical compositions and unit dosage forms that combine:
- A specific compound of Formula (I) (or a hydrate) in high loading,
- Effervescent agents in a defined quantity range,
- Performance defined by “satisfactory in vitro dissolution at low pH.”
All presented claims are formulation-focused. The scope is not method-of-treatment and does not claim routes of synthesis. It is centered on composition composition (solid dosage compositions) with tight quantitative constraints that limit what can be designed around.
How are the independent and dependent claims structured?
Claim types and hierarchy
From the claim set provided:
- Claim 1 is the baseline composition claim.
- Claims 2-7 narrow composition parameters (loading %, effervescent amount, effervescent identity, cation identity, hydrate form, and an additional structure reference).
- Claim 8 is a unit dosage-form claim that adds absolute dose thresholds for both the active and effervescent components.
Claim 1 (core composition boundary)
Claim 1
- A solid pharmaceutical composition comprising:
- > 15% w/w of compound of Formula (I) (or hydrate thereof)
- where each X+ is a monovalent cation
- and/or hydrate
- plus one or more effervescent agents in an amount sufficient for “satisfactory in vitro dissolution at low pH”
- plus one or more pharmaceutically acceptable ingredients.
Immediate scope implications
- The claim is broad on:
- the effervescent system identity (no single agent is required in Claim 1)
- additional excipients
- cation type being any monovalent cation
- hydrate status because “and/or a hydrate thereof” appears in the definition of the compound component
- The claim is narrower on:
- active loading is constrained to be strictly greater than 15% w/w
- dissolution performance is used as a functional limiter (“satisfactory in vitro dissolution at low pH”), which can drive claim construction around experimental evidence and disclosed benchmarks in the specification (not provided here).
Claims 2 and 3 (numeric tightening)
Claim 2
- Composition of Claim 1 comprising ≥ 25% w/w of Formula (I) and/or hydrate.
Claim 3
- Composition of Claim 1 comprising ≤ 20% w/w of the effervescent agent(s).
Immediate scope implications
- These two claims together create a formulation “box” for infringement:
- Active is higher (≥25% or at least >15% depending on which claim theory is asserted)
- Effervescent system is capped (≤20% w/w if Claim 3 is asserted)
Claims 4-7 (identity and form locks)
Claim 4
- Effervescent agent is sodium hydrogen carbonate.
Claim 5
- Each X+ is specifically sodium cation (Na+).
Claim 6
- Formula (I) is specifically in the hexahydrate form.
Claim 7
- Formula (I) is in the form of Formula (II) (as defined in the patent text; the structure is not shown in your prompt).
Immediate scope implications
- These dependent claims narrow to specific:
- effervescent chemistry (bicarbonate only)
- counterion identity (Na+ only)
- solid form (hexahydrate only)
- They increase the likelihood of a strong infringement position when the accused product matches these specific selections.
- They also create clear design-around options:
- switch from bicarbonate to another effervescent system (for example, carbonate/citric combinations)
- use a different monovalent cation form (for example, potassium or lithium) if the chemistry and salt form can be established
- change hydrate form away from hexahydrate
Claim 8 (unit dosage form with absolute mass limits)
Claim 8
- A unit dosage form comprising:
- ≥ 60 mg of Formula (I) where X+ is monovalent and/or hydrate
- ≤ 110 mg of one or more effervescent agents sufficient for low-pH dissolution
- plus pharmaceutically acceptable ingredients.
Immediate scope implications
- Claim 8 introduces absolute dosing constraints that can be decisive in enforcement for marketed products (tablet/sachet/capsule fill).
- It can capture unit-dose products even when formulations differ in excipient selection, as long as:
- active dose is at least 60 mg per unit
- effervescent mass per unit does not exceed 110 mg
- dissolution performance requirement is met
What is the effective claim “scope map” (coverage and limits)?
Coverage elements that can establish infringement
To fall within Claim 1, an accused product must align on all three pillars:
- Solid pharmaceutical composition
- Contains >15% w/w of Formula (I) or a hydrate
- Contains effervescent agents at an amount sufficient for satisfactory in vitro dissolution at low pH
Limits that narrow infringement risk
- Active loading:
- Claim 1: >15% w/w
- Claim 2: ≥25% w/w
- Effervescent amount:
- Claim 3: ≤20% w/w
- Claim 8: ≤110 mg per unit dosage
- Identity locks (for narrower dependent claims):
- bicarbonate is required for Claim 4
- sodium counterion for Claim 5
- hexahydrate for Claim 6
- Formula (II) for Claim 7
Claim cross-coverage logic
- A product with high active loading and effervescent capped can fall into multiple claims simultaneously.
- A product that changes effervescent agent identity or hydrate form can still be caught under Claim 1 unless the design-around also breaks the “satisfactory dissolution at low pH” requirement or the loading thresholds.
Where are the key legal and technical fault lines in these claims?
1) The functional dissolution limiter
Claim 1 requires effervescence “sufficient to provide satisfactory in vitro dissolution at low pH.” This is:
- a functional requirement rather than a purely quantitative listing
- a term that typically turns on how the patent defines the dissolution test and acceptance criteria in the specification.
In enforcement, this usually becomes the hinge for whether “effervescent amount” is met beyond nominal amounts.
2) Hydrate and salt-family coverage
The claims say Formula (I) and/or a hydrate thereof, and X+ is monovalent. That creates:
- potential coverage for multiple hydrate states if they remain within the defined “compound of Formula (I)” scope
- potential coverage for a broader salt family if X+ can be other monovalent cations (unless the specification limits the operational definition).
3) The quantitative “boxes” are enforceable
-
15% w/w (Claim 1)
- ≥25% w/w (Claim 2)
- ≤20% w/w effervescent (Claim 3)
- ≥60 mg active and ≤110 mg effervescent per unit (Claim 8)
These are straightforward to measure in a formulation and are likely to be used in both litigation and regulatory comparability.
How does this patent likely sit in a US formulation patent landscape?
Without the actual publication number, assignee, filing date, or the patent family chain, a complete US landscape across:
- continuations
- related formulation patents
- competing effervescent solid dispersions
- generic-design-around patents
cannot be enumerated from the claim text alone.
However, the claim architecture is consistent with a common US strategy in solid oral reformulations:
- claim the specific active/hydrate
- claim the high-loading solid composition
- claim the effervescent system and ratio constraints
- include unit-dose numerical constraints for commercial relevance.
This means the patent likely clusters with:
- earlier patents defining Formula (I) itself (API and salt/hydrate generation)
- later patents focusing on solid form, effervescent, and fast dissolution performance.
From a business perspective, a “real” landscape decision hinges on identifying:
- whether there are earlier API patents that block even a non-effervescent design
- whether there are later patents that expand beyond the current effervescent dissolution claims
- whether third parties hold platform patents on effervescence/dissolution at low pH (which can constrain design-around options even if the specific Claim 1 elements are avoided).
Given only the claim snippets you provided, the only actionable landscape conclusions that can be stated are those derived directly from the claim elements themselves.
What are the most direct design-around vectors implied by these claims?
These are the clearest switches that would target non-infringement of specific dependent claims and raise infringement defenses for Claim 1 by attacking the quantitative and functional boundaries.
Vector A: reduce active loading below Claim 1 threshold
- Move to ≤15% w/w Formula (I)/hydrate.
- This avoids Claim 1’s “greater than 15% w/w” requirement.
Vector B: cap or shift effervescent amount to violate numeric limitations
- For compositions within Claim 1, a formulation exceeding 20% w/w effervescent aims to avoid Claim 3, but may still be within Claim 1 if dissolution remains satisfactory.
- For unit dosage forms, exceed 110 mg effervescent per unit to avoid Claim 8.
Vector C: swap effervescent agent identity
- Avoid sodium hydrogen carbonate to target Claim 4.
- If Claim 1 is still met (dissolution at low pH), this may not fully avoid infringement, but it narrows a dependent-claim path.
Vector D: change counterion away from sodium
- Avoid X+ = Na+ to target Claim 5.
- This must be paired with valid formulation reality: the API must be the alternate monovalent cation form still falling outside “compound of Formula (I)” in the claim construction (depends on the patent’s definition of Formula (I) salts).
Vector E: switch hydrate away from hexahydrate
- Avoid hexahydrate to target Claim 6.
- Again, this is only fully protective if the alternative solid form is not encompassed by “compound of Formula (I) and/or hydrate thereof” as construed.
Vector F: avoid the specific structural instantiation in Claim 7
- Ensure the API form does not match “Formula (II)” as defined in the patent.
What evidence is likely to matter most if this patent is litigated or cleared for generic formulation?
Based on the claim language alone, the critical evidentiary categories are:
-
Formulation composition testing
- Confirm active content as % w/w (for Claims 1-3)
- Confirm active mass per unit (Claim 8)
- Confirm effervescent mass per unit (Claim 8)
- Confirm effervescent agent identity (Claims 4 and possibly Claim 1 depending on construction)
-
In vitro dissolution at low pH
- Whether the effervescent system produces “satisfactory” dissolution per the patent’s methodology
- Whether results are reproducible and consistent with “sufficient to provide satisfactory” language
-
Solid-state characterization
- Whether the API is the claimed hydrate (Claim 6)
- Whether polymorph/solvate states fall within or outside the claimed hydrate category
- Whether the cation form matches the required X+ constraints (Claim 5)
Key Takeaways
- US 8,771,648 claims solid effervescent oral compositions using a Formula (I) compound (or hydrate) at >15% w/w with effervescence sufficient for low-pH dissolution.
- The claim set tightens coverage with active loading (≥25% w/w), effervescent cap (≤20% w/w), and unit-dose limits (≥60 mg active and ≤110 mg effervescent).
- Dependent claims lock in specific design elements: sodium hydrogen carbonate, Na+ counterion, and hexahydrate form.
- The strongest infringement battleground is the functional limiter: “satisfactory in vitro dissolution at low pH.” Quantitative thresholds then determine which claims are triggered.
FAQs
1) Does US 8,771,648 cover both compositions and unit dosage forms?
Yes. Claim 1 covers a solid pharmaceutical composition; Claim 8 covers a unit dosage form with absolute dose limits for both active and effervescent components.
2) What is the minimum active loading for the baseline composition claim?
Claim 1 requires greater than 15% w/w of Formula (I) and/or its hydrate.
3) What effervescent quantitative limit appears in the composition claims?
Claim 3 requires less than or equal to 20% w/w of the effervescent agent(s).
4) Which dependent claim requires sodium hydrogen carbonate?
Claim 4 specifies the effervescent agent is sodium hydrogen carbonate.
5) What unit-dose limits must be met for Claim 8?
Claim 8 requires at least 60 mg of Formula (I) per unit and no more than 110 mg of effervescent agent per unit.
References
[1] US Patent 8,771,648 (claim text provided by user).
